12:00 AM
Feb 06, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

IHC immunohistochemistry assay regulatory update

The U.K.'s NICE issued draft guidance recommending against the use of 3 breast cancer diagnostics to guide decisions about chemotherapy use in women with estrogen receptor-positive, lymph node-negative, HER2-negative breast cancer. NICE said it could not consider the tests cost effective because evidence for the tests' clinical efficacy is "limited." The committee noted that most studies were retrospective, which it...

Read the full 280 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >